Pfizer's innovative health president Albert Bourla, though, reminded investors on the call that the company had successfully "managed … price competition in the past, and we will do it in the future." RELATED: With Novartis' Kisqali, Pfizer faces its first in-class threat for Ibrance Meanwhile, the company managed a beat on the earnings front thanks to lower expenses and a gain on divestments, reporting per-share profits of 69 cents that topped the 67-cent consensus estimate. It also reaffirmed its 2017 guidance, and "and we continue to maintain the numbers are well within reach," Barclays analyst Geoff Meacham wrote in an investor note.